State of Alaska Department of Revenue Lowers Stake in IQVIA Holdings Inc. (NYSE:IQV)

State of Alaska Department of Revenue lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,887 shares of the medical research company’s stock after selling 465 shares during the quarter. State of Alaska Department of Revenue’s holdings in IQVIA were worth $5,675,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC acquired a new stake in IQVIA in the 4th quarter worth about $33,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the period. Assetmark Inc. increased its stake in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in shares of IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after acquiring an additional 99 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $208.13 on Friday. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market cap of $37.78 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 2.15 and a beta of 1.48. The business’s 50 day moving average is $200.53 and its two-hundred day moving average is $219.80.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. Analysts forecast that IQVIA Holdings Inc. will post 10.18 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on IQV. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Truist Financial cut their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Stephens started coverage on shares of IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.